Let Us Solve Your Solubility/Bioavailability Issues.

LLS Health Feasibility Programs

The CDMO Division of LLS Health regularly receives inquiries on overcoming poor solubility/bioavailability, developing long-acting dosage forms, and increasing the lifespan of implantable products. Our passion for overcoming complex formulation challenges helps us find the best solution to achieve your goals.

Why LLS Health?

We offer feasibility programs designed to accelerate product development in these focus areas. These programs utilize trusted technologies to provide early-stage support in relatively quick, cost-effective packages. If a feasibility program proves successful, LLS Health is positioned to provide ongoing optimization, scale-up, and manufacturing for each product type. Learn more about our feasibility offerings at the links below.

Nanomilling Feasibility Program

Nanomilling is an efficient, reproducible, and scalable approach for improving the rate of dissolution and bioavailability of BCS Class II and IV compounds. If you have an insoluble API, contact us to learn how nanomilling can help solve your formulation challenges, and let us take your product from concept to commercial.

Dexamethasone-Loaded Polymers for Implantable Systems

LLS Health is addressing the growing need for implantable materials with our dexamethasone-loaded polymer offering. By combining trusted, biocompatible polymers (silicone, TPU, EVA, PLGA, and others) with a safe, effective anti-inflammatory agent (dexamethasone), we can supply ready-made material that is ideal for prototyping and product development efforts.

Microsphere Feasibility Program

These polymer-based systems may be able to encapsulate large quantities of API for parenteral or ophthalmic administration and enable the delivery of both small and large molecules for weeks or months at a time.

Long-Acting Implant Feasibility Program

Polymeric LAIs are an area of growing interest in the pharmaceutical industry as they offer benefits over other dosage forms in designing platforms for drug delivery. The marketed intravitreal LAI, Ozurdex®, was the first drug therapy approved by the FDA for long-acting treatment of macular edema, with annual sales of $400 M in 2019.